Goldman Sachs’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$26.1M Buy
1,865,324
+193,246
+12% +$2.7M ﹤0.01% 1586
2025
Q1
$22.7M Buy
1,672,078
+614,555
+58% +$8.35M ﹤0.01% 1608
2024
Q4
$21.6M Sell
1,057,523
-310,298
-23% -$6.32M ﹤0.01% 1726
2024
Q3
$39.8M Buy
1,367,821
+148,896
+12% +$4.34M 0.01% 1223
2024
Q2
$28.3M Buy
1,218,925
+314,564
+35% +$7.3M ﹤0.01% 1336
2024
Q1
$18.6M Buy
904,361
+510,556
+130% +$10.5M ﹤0.01% 1601
2023
Q4
$8.45M Sell
393,805
-13,588
-3% -$292K ﹤0.01% 2209
2023
Q3
$8.4M Sell
407,393
-237,521
-37% -$4.9M ﹤0.01% 2105
2023
Q2
$19M Buy
644,914
+72,071
+13% +$2.13M ﹤0.01% 1593
2023
Q1
$13.2M Sell
572,843
-198,609
-26% -$4.58M ﹤0.01% 1807
2022
Q4
$21.5M Buy
771,452
+43,180
+6% +$1.2M 0.01% 1556
2022
Q3
$22.4M Buy
728,272
+307,530
+73% +$9.44M 0.01% 1516
2022
Q2
$12.4M Buy
420,742
+14,514
+4% +$427K ﹤0.01% 1952
2022
Q1
$13.1M Sell
406,228
-4,536
-1% -$146K ﹤0.01% 2019
2021
Q4
$18.3M Sell
410,764
-645,794
-61% -$28.8M ﹤0.01% 1805
2021
Q3
$53.3M Buy
1,056,558
+468,740
+80% +$23.6M 0.01% 1063
2021
Q2
$46.1M Sell
587,818
-60,033
-9% -$4.71M 0.01% 1138
2021
Q1
$37M Sell
647,851
-54,543
-8% -$3.11M 0.01% 1233
2020
Q4
$58.8M Buy
702,394
+196,852
+39% +$16.5M 0.02% 857
2020
Q3
$18.1M Buy
505,542
+277,733
+122% +$9.95M 0.01% 1546
2020
Q2
$5.51M Buy
227,809
+96,444
+73% +$2.33M ﹤0.01% 2287
2020
Q1
$2.3M Buy
131,365
+30,578
+30% +$535K ﹤0.01% 2676
2019
Q4
$1.76M Sell
100,787
-3,300
-3% -$57.5K ﹤0.01% 3011
2019
Q3
$1.6M Buy
104,087
+8,029
+8% +$123K ﹤0.01% 2953
2019
Q2
$1.99M Sell
96,058
-11,236
-10% -$233K ﹤0.01% 2828
2019
Q1
$2.49M Buy
107,294
+39,016
+57% +$906K ﹤0.01% 2811
2018
Q4
$1.41M Buy
68,278
+56,100
+461% +$1.16M ﹤0.01% 2980
2018
Q3
$265K Sell
12,178
-41,352
-77% -$900K ﹤0.01% 3711
2018
Q2
$816K Sell
53,530
-79,005
-60% -$1.2M ﹤0.01% 3303
2018
Q1
$2.61M Sell
132,535
-7,441
-5% -$147K ﹤0.01% 2720
2017
Q4
$2.19M Buy
+139,976
New +$2.19M ﹤0.01% 2787